Core Insights - Cognition Therapeutics is advancing the clinical development of zervimesine for treating psychosis associated with dementia with Lewy bodies (DLB), with a meeting with the FDA Division of Psychiatry expected by mid-2026 [1][2] Clinical Development - The company has developed a clinical plan for zervimesine, targeting a patient population with no approved treatment options for DLB psychosis [2] - The 545-patient 'START' trial in early Alzheimer's disease has completed enrollment, with results expected in 2027 to inform future development [2][7] - The company plans to advance zervimesine into late-stage trials for DLB psychosis based on strong efficacy signals observed in previous studies [10] Financial Results - As of December 31, 2025, the company reported cash and cash equivalents of approximately $37.0 million, with total obligated grant funds remaining at $35.7 million, indicating sufficient cash to fund operations through Q2 2027 [4] - Research and development expenses decreased to $37.2 million in 2025 from $41.7 million in 2024, attributed to the completion of clinical trials [5] - General and administrative expenses also decreased to $10.6 million in 2025 from $12.3 million in 2024, primarily due to reduced stock-based compensation [6] - The net loss for 2025 was $23.5 million, or $(0.32) per share, an improvement from a net loss of $34.0 million, or $(0.86) per share, in 2024 [6][15] Operational Highlights - The company launched an expanded access program for DLB patients and appointed Dr. David Weinstein as VP of clinical development [7] - A meeting with the FDA is planned to discuss the path forward for zervimesine in treating DLB psychosis [7] - The company has conducted an end-of-Phase 2 meeting with the FDA and received alignment on the development plan for zervimesine in Alzheimer's disease [7]

Core Insights - Cognition Therapeutics, Inc. presented findings from the Phase 2 COG1201 SHIMMER study on zervimesine (CT1812) for dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Conference, highlighting its potential to treat neuropsychiatric symptoms associated with DLB [1][2] Group 1: Study Findings - The Phase 2 SHIMMER study demonstrated an 86% slowing of decline on the neuropsychiatric index (NPI-12) with zervimesine treatment compared to placebo, indicating its unique disease-modifying mechanism of action [2][5] - Zervimesine showed a robust impact on neuropsychiatric symptoms, cognitive fluctuations, memory, movement symptoms, and daily living activities, making it a potential alternative for DLB patients who cannot tolerate traditional antipsychotics [3][6] Group 2: Clinical Development - Based on the Phase 2 results and a recent meeting with the FDA, the company plans to advance zervimesine for treating DLB psychosis, which includes symptoms like hallucinations and agitation that worsen as the disease progresses [5][10] - Zervimesine has been generally well tolerated in clinical studies, and the company aims to move it into late-stage clinical trials for DLB psychosis [10][11] Group 3: Market Context - Approximately 75% of DLB patients experience psychosis, leading to significant burdens on patients and caregivers, and highlighting the need for effective treatments as traditional antipsychotics are often contraindicated [7][9] - Cognition Therapeutics is focused on developing novel therapies for neurodegenerative diseases, with zervimesine being a key candidate backed by nearly $200 million in grants [9][10]

Core Insights - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and has conducted a Type C meeting with the FDA to discuss the Phase 2b study [1][2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [4] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by an $81 million grant from the National Institute of Aging [4] Drug Development - Zervimesine is an oral, once-daily pill aimed at treating CNS diseases, specifically targeting the toxic effects of Aβ and ɑ-synuclein proteins that contribute to neurodegeneration [2] - The drug has shown promise in interrupting the toxic effects of these proteins, potentially slowing disease progression and improving patient quality of life [2] Regulatory Engagement - The FDA meeting was described as productive, focusing on clinically meaningful endpoints for the upcoming Phase 2b study [2] - The company anticipates receiving meeting minutes from the FDA later this quarter, indicating ongoing communication to advance clinical development [2]

Core Insights - Cognition Therapeutics, Inc. has successfully completed enrollment in its expanded access program for zervimesine, with participants receiving 100 mg daily for up to one year [1][2] - The company has scheduled a Type C meeting with the U.S. FDA for the second half of January to discuss the proposed design of a Phase 3 program for zervimesine in dementia with Lewy bodies (DLB) [2][3] Expanded Access Program - The COG1202 expanded access program is open-label and includes eligible participants from the Phase 2 SHIMMER study and additional patients diagnosed with mild-to-moderate DLB [3] - Dr. James E. Galvin is the lead investigator for this multi-center program [3] Zervimesine (CT1812) - Zervimesine is an investigational oral medication aimed at treating CNS diseases, specifically Alzheimer's disease and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [4] - The drug has shown a good safety profile in clinical studies to date [4][5] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies in early Alzheimer's disease [6]

Core Insights - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative disorders [3] - The company will participate in the 37th Annual Piper Sandler Healthcare Conference, with a discussion scheduled for December 3, 2025 [1][2] Company Overview - Cognition Therapeutics specializes in small molecule therapeutics targeting age-related degenerative disorders of the central nervous system [3] - The company has completed Phase 2 studies for its lead candidate, zervimesine (CT1812), in conditions such as dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [3] - An ongoing Phase 2 START Study (NCT05531656) is focused on early Alzheimer's disease [3] - Zervimesine is believed to interact with the sigma-2 receptor, offering a distinct mechanism compared to other treatments for degenerative diseases [3]

Core Insights - Anavex Life Sciences Corp. has successfully developed a once-daily oral tablet formulation for the ANAVEX3-71 program, demonstrating safety and tolerability in a Phase 1b clinical trial [1][2][3] Group 1: Product Development - The new modified-release oral tablet of ANAVEX3-71 shows superior pharmacokinetics compared to the immediate-release oral capsule, allowing for once-daily dosing [1][2] - The Phase 1b clinical trial (ANAVEX3-71-002) confirmed the pharmacokinetic profile supportive of once-daily dosing and consistent safety profile with prior studies [2][3] Group 2: Mechanism of Action - ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, which has the potential to treat all symptom domains of schizophrenia without the side effects associated with standard antipsychotics [3][4] - The drug candidate has shown beneficial effects on mitochondrial dysfunction and neuroinflammation in preclinical trials, indicating its potential for treating Alzheimer's disease and other CNS disorders [4]

Core Viewpoint - Cognition Therapeutics, Inc. has successfully closed a registered direct offering of 14,700,000 shares of common stock at a price of $2.05 per share, raising approximately $30 million in gross proceeds to advance its drug zervimesine for neurodegenerative disorders [1][2]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6]. - The company has completed Phase 2 studies for its lead candidate, zervimesine (CT1812), targeting dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [6]. Product Information - Zervimesine (CT1812) is an investigational oral medication designed for the treatment of CNS diseases, specifically Alzheimer's disease and dementia with Lewy bodies [4]. - The drug aims to interrupt the toxic effects of Aβ and ɑ-synuclein proteins, which are associated with neurodegeneration, potentially slowing disease progression and improving patient quality of life [4]. Financial Details - The offering was facilitated by Titan Partners Group, which acted as the sole placement agent [2]. - The shares were offered under a shelf registration statement previously filed with the U.S. Securities and Exchange Commission, which was declared effective on January 3, 2023 [2].

Core Viewpoint - Cognition Therapeutics, Inc. has announced a registered direct offering of 14,700,000 shares of common stock, expected to generate approximately $30 million in gross proceeds to fund Phase 3 programs of zervimesine for neurodegenerative disorders and for general corporate purposes [1][2]. Group 1: Offering Details - The offering is made to two new fundamental institutional investors, including a prominent global investment manager [2]. - The closing of the offering is anticipated to occur on or about August 29, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the preparation of Phase 3 programs of zervimesine in neurodegenerative disorders, as well as for working capital and general corporate purposes [2]. Group 3: Company Background - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [5]. - The company has completed Phase 2 studies of zervimesine in conditions such as dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [5]. - The ongoing Phase 2 START study in early Alzheimer's disease is supported by $81 million in grant funding from the National Institute of Aging [5].

Core Points - Cognition Therapeutics, Inc. has regained compliance with Nasdaq's minimum share price requirement under Rule 5550(a)(2) [1][2] - The company achieved a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, with the requirement fulfilled on August 25, 2025 [2] - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative disorders [3] Company Overview - Cognition Therapeutics is currently developing zervimesine (CT1812), targeting dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [3] - The Phase 2 START study in early Alzheimer's disease is ongoing, supported by $81 million in grants from the National Institute of Aging [3] - The mechanism of zervimesine involves interaction with the sigma-2 receptor, which is distinct from other treatment approaches for degenerative diseases [3]

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and has a portfolio of drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial property [4]